Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ALPHARETTA, Ga., Aug. 08, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it will participate in three upcoming events.
Clearside will host a Key Opinion Leader (“KOL”) luncheon event on Thursday, August 10, 2017 in Boston, MA. The invited speaker for this event is Dr. David M. Brown, a prominent Houston, TX-based retinal specialist and thought leader on the research and treatment of retinal vein occlusion (“RVO”), diabetic macular edema (“DME”) and age-related macular degeneration (“AMD”). The KOL lunch event will not be webcast.
Clearside’s Chief Executive Officer and President, Daniel H. White, will participate in a panel discussion on retinal drug delivery at the Ophthalmology Innovation Summit (“OIS”) to be held Thursday, August 10, 2017 in conjunction with the 35th Annual Scientific Meeting of the American Society of Retinal Specialists (“ASRS”) in Boston, MA. The panel discussion at OIS@ASRS will not be webcast.
Clearside management will also participate in the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at the Le Parker Meridien Hotel in New York, NY. Mr. White will participate in a lunch panel entitled, “New Technologies in Drug Delivery,” at 11:30 a.m. ET and will present at 2:30 p.m. ET. A live webcast of the presentation can be accessed on Clearside’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, DME and AMD. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations (678) 270-3631 [email protected] Charles Deignan Chief Financial Officer (678) 270-4005 [email protected]
